CompletedNCT00473434
About this title
An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia
Read the official source — NCT00473434Official study titleAn Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Janssen-Cilag Pty Ltd
CompletedNCT01646827
About this title
An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia
Read the official source — NCT01646827Official study titleAn Open-label, Randomized, Parallel Arm, Bioavailability Trial of Aripiprazole IM Depot Administered in the Deltoid or Gluteal Muscle in Adult Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including CerritosSchizophreniaMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT00246272
About this title
An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone
Read the official source — NCT00246272Official study titleAn Open-label Study Evaluating the Maintenance of Clinical Effect in Adults With Schizophrenia Switched From RISPERDAL® Tablets (Risperidone) to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Janssen-Ortho Inc., Canada
CompletedNCT02320032
Official study titleA Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Alkermes, Inc.
CompletedNCT03287505
What is this study about?This study evaluated the safety of Aripiprazole IM Depot for people with schizophrenia.
This study has finished and is no longer accepting participants.
In BeijingSchizophreniaMedication studyAges 18–64
- Countries
- China
- Sponsor
- Otsuka Beijing Research Institute
CompletedNCT03172871
Official study titleA Multicenter, Randomized, Double-blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Aripiprazole Intramuscular Depot in the Acute Treatment of Adults With Schizophrenia
This study has finished and is no longer accepting participants.
In BeijingSchizophreniaMedication studyAges 18–65
- Countries
- China
- Sponsor
- Otsuka Beijing Research Institute
CompletedNCT00095810
About this title
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
Read the official source — NCT00095810Official study titleAn Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease
This study has finished and is no longer accepting participants.
In AlbanySchizophreniaMedication studyAges 50+
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT01438060
About this title
Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
Read the official source — NCT01438060Official study titleA Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 55–95
- Countries
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)